Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 215

1.

Advances in the monitoring of anti-P2Y12 therapy.

Harrison P.

Platelets. 2012;23(7):510-25. Epub 2012 Aug 23. Review.

PMID:
22916724
2.

New anti-platelet agents: the end of resistance?

Kastrati A.

Thromb Res. 2012 Oct;130 Suppl 1:S53-5. doi: 10.1016/j.thromres.2012.08.275. Review.

PMID:
23026663
3.

Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry.

Olivier CB, Diehl P, Schnabel K, Weik P, Zhou Q, Bode C, Moser M.

Thromb Haemost. 2014 Feb;111(2):266-72. doi: 10.1160/TH13-06-0508. Epub 2013 Oct 31.

PMID:
24172891
4.

Evaluation of ticagrelor pharmacodynamic interactions with reversibly binding or non-reversibly binding P2Y(12) antagonists in an ex-vivo canine model.

Ravnefjord A, Weilitz J, Emanuelsson BM, van Giezen JJ.

Thromb Res. 2012 Oct;130(4):622-8. doi: 10.1016/j.thromres.2012.07.021. Epub 2012 Aug 19.

PMID:
22909827
5.

Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study.

Alexopoulos D, Galati A, Xanthopoulou I, Mavronasiou E, Kassimis G, Theodoropoulos KC, Makris G, Damelou A, Tsigkas G, Hahalis G, Davlouros P.

J Am Coll Cardiol. 2012 Jul 17;60(3):193-9. doi: 10.1016/j.jacc.2012.03.050.

6.

Comparative pharmacokinetics and pharmacodynamics of platelet adenosine diphosphate receptor antagonists and their clinical implications.

Floyd CN, Passacquale G, Ferro A.

Clin Pharmacokinet. 2012 Jul 1;51(7):429-42. doi: 10.2165/11630740-000000000-00000. Review.

PMID:
22568693
7.

P2Y12 platelet inhibition in clinical practice.

Damman P, Woudstra P, Kuijt WJ, de Winter RJ, James SK.

J Thromb Thrombolysis. 2012 Feb;33(2):143-53. doi: 10.1007/s11239-011-0667-5. Review.

8.

The platelet P2Y₁₂ receptor for adenosine diphosphate: congenital and drug-induced defects.

Cattaneo M.

Blood. 2011 Feb 17;117(7):2102-12. doi: 10.1182/blood-2010-08-263111. Epub 2010 Oct 21. Review.

10.

Comparison of patient intake of ticagrelor, prasugrel, or clopidogrel on restoring platelet function by donor platelets.

Scharbert G, Wetzel L, Schrottmaier WC, Kral JB, Weber T, Assinger A.

Transfusion. 2015 Jun;55(6):1320-6. doi: 10.1111/trf.12977. Epub 2015 Jan 15.

PMID:
25641006
11.

A comparison of INNOVANCE® PFA P2Y and VerifyNow P2Y12 assay for the assessment of clopidogrel resistance in patients undergoing percutaneous coronary intervention.

Jang J, Lim J, Chang K, Kim Y, Kim M, Park HI, Kim J, Shin S.

J Clin Lab Anal. 2012 Jul;26(4):262-6. doi: 10.1002/jcla.21515.

PMID:
22811359
12.

Clinical use of clopidogrel.

Sarafoff N, Byrne RA, Sibbing D.

Curr Pharm Des. 2012;18(33):5224-39. Review.

PMID:
22724411
13.

Pretreatment platelet reactivity contribution to residual, post-treatment platelet reactivity in prasugrel-treated and ticagrelor-treated patients.

Alexopoulos D, Xanthopoulou I, Davlouros P, Tsigkas G, Damelou A, Theodoropoulos KC, Gkizas V, Hahalis G.

J Thromb Haemost. 2013 Feb;11(2):381-4. doi: 10.1111/jth.12095. No abstract available.

14.

Clopidogrel resistance: identifying and overcoming a barrier to effective antiplatelet treatment.

Uchiyama S.

Cardiovasc Ther. 2011 Dec;29(6):e100-11. doi: 10.1111/j.1755-5922.2010.00202.x. Epub 2011 Jul 31. Review.

PMID:
21883990
15.

Prasugrel resistance: fact or fiction.

Alexopoulos D.

Platelets. 2012;23(2):83-90. doi: 10.3109/09537104.2011.600478. Epub 2011 Jul 25. Review.

PMID:
21787175
16.

Resistance to anti-platelet agents.

Cattaneo M.

Thromb Res. 2011 Feb;127 Suppl 3:S61-3. doi: 10.1016/S0049-3848(11)70017-2.

PMID:
21262444
17.

Thienopyridines and other ADP-receptor antagonists.

Bernlochner I, Sibbing D.

Handb Exp Pharmacol. 2012;(210):165-98. doi: 10.1007/978-3-642-29423-5_7. Review.

PMID:
22918731
18.

Response variability to P2Y12 receptor inhibitors: expectations and reality.

Siller-Matula JM, Trenk D, Schrör K, Gawaz M, Kristensen SD, Storey RF, Huber K; EPA (European Platelet Academy).

JACC Cardiovasc Interv. 2013 Nov;6(11):1111-28. doi: 10.1016/j.jcin.2013.06.011. Review.

19.

Bleeding manifestations of congenital and drug-induced defects of the platelet P2Y12 receptor for adenosine diphosphate.

Cattaneo M.

Thromb Haemost. 2011 May;105 Suppl 1:S67-74. doi: 10.1160/THS10-11-0742. Epub 2011 Apr 11. Review.

PMID:
21479342
20.

Prasugrel offers consistent platelet control in appropriate patients requiring treatment.

Aalbers J.

Cardiovasc J Afr. 2011 Mar-Apr;22(2):107, 109. No abstract available.

Supplemental Content

Support Center